Literature DB >> 22529031

Characterization of a new human melanoma cell line with CD133 expression.

Rosario Gil-Benso1, Carlos Monteagudo, Miguel Cerdá-Nicolás, Robert C Callaghan, Sandra Pinto, Alicia Martínez-Romero, Ana Pellín-Carcelén, Teresa San-Miguel, Juan C Cigudosa, Concha López-Ginés.   

Abstract

A novel human malignant melanoma cell line, designated MEL-RC08, was established from a pericranial metastasis of a malignant melanoma of the skin. The cell line has been subcultured for more than 150 passages and is tumorigenic in nude mice. Growth kinetics, cytogenetics, flow cytometry, and molecular techniques for analysis of the genes implicated in cell cycle control; mutations in BRAF, NRAS, C-KiT, RB, and TP53 genes; and amplification of MDM2, CDK4, and cyclin D1 have been studied. Cytogenetically, the tumor and the cell line showed a hypertriploid karyotype with many clonal numeric and structural abnormalities. DNA flow cytometry showed an aneuploid peak with a DNA index value of 1.5. Mutations in TP53 and BRAF genes were demonstrated in both tumor and cell line. Furthermore, stem cell marker CD133 expression was detected in most cells, together with other stem cell markers, suggesting the presence of cells with tumor-initiating potential in this cell line.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22529031     DOI: 10.1007/s13577-011-0027-y

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  30 in total

1.  A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Authors:  Alexander Roesch; Mizuho Fukunaga-Kalabis; Elizabeth C Schmidt; Susan E Zabierowski; Patricia A Brafford; Adina Vultur; Devraj Basu; Phyllis Gimotty; Thomas Vogt; Meenhard Herlyn
Journal:  Cell       Date:  2010-05-14       Impact factor: 41.582

2.  The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma.

Authors:  Germana Rappa; Oystein Fodstad; Aurelio Lorico
Journal:  Stem Cells       Date:  2008-09-18       Impact factor: 6.277

3.  High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival.

Authors:  A Dietrich; E Tanczos; W Vanscheidt; E Schöpf; J C Simon
Journal:  Eur J Cancer       Date:  1997-05       Impact factor: 9.162

4.  Increased expression of stem cell markers in malignant melanoma.

Authors:  Walter M Klein; Bryan P Wu; Shuping Zhao; Hong Wu; Andres J P Klein-Szanto; Steven R Tahan
Journal:  Mod Pathol       Date:  2006-11-24       Impact factor: 7.842

5.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

Review 6.  Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146.

Authors:  Allal Ouhtit; Rajiv L Gaur; Zakaria Y Abd Elmageed; Augusta Fernando; Rajesh Thouta; Alison K Trappey; Mohamed E Abdraboh; Hassan I El-Sayyad; Prakash Rao; Madhwa G H Raj
Journal:  Biochim Biophys Acta       Date:  2009-01-29

Review 7.  CD133: molecule of the moment.

Authors:  D Mizrak; M Brittan; M R Alison
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

8.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Identification of progenitor cancer stem cell in lentigo maligna melanoma.

Authors:  M R Bongiorno; S Doukaki; F Malleo; M Aricò
Journal:  Dermatol Ther       Date:  2008-07       Impact factor: 2.851

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  5 in total

Review 1.  TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.

Authors:  Jakub Litak; Cezary Grochowski; Joanna Litak; Ida Osuchowska; Krzysztof Gosik; Elżbieta Radzikowska; Piotr Kamieniak; Jacek Rolinski
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

2.  Expression of the Chemokine Receptors CXCR3, CXCR4, CXCR7 and Their Ligands in Rhabdomyosarcoma.

Authors:  Teresa San-Miguel; Sandra Pinto; Lara Navarro; Robert C Callaghan; Carlos Monteagudo; Concha López-Ginés; Miguel Cerdá-Nicolás; Rosario Gil-Benso
Journal:  Pathol Oncol Res       Date:  2015-06-03       Impact factor: 3.201

3.  Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide.

Authors:  Javier Megías; Alba Martínez; Teresa San-Miguel; Rosario Gil-Benso; Lisandra Muñoz-Hidalgo; David Albert-Bellver; Amara Carratalá; Daniel Gozalbo; Concha López-Ginés; María Luisa Gil; Miguel Cerdá-Nicolás
Journal:  Invest New Drugs       Date:  2019-05-11       Impact factor: 3.850

4.  Characterization of the new human pleomorphic undifferentiated sarcoma TP53-null cell line mfh-val2.

Authors:  Rosario Gil-Benso; Javier Megías; Teresa San-Miguel; Sandra Pinto; Robert C Callaghan; Concha López-Ginés; Miguel Cerdá-Nicolás
Journal:  Cytotechnology       Date:  2017-07-04       Impact factor: 2.058

5.  Intracellular coexpression of CXC- and CC- chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation.

Authors:  Sandra Pinto; Alicia Martínez-Romero; José-Enrique O'Connor; Rosario Gil-Benso; Teresa San-Miguel; Liria Terrádez; Carlos Monteagudo; Robert C Callaghan
Journal:  BMC Cancer       Date:  2014-02-22       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.